Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data

Area of Science:

• Pharmacology
• Nutraceuticals
• Clinical Trials

Background:

• Polyphenolic compounds offer health benefits but face bioavailability challenges.
• Resveratrol, a notable polyphenol, has limited human bioavailability data from in vitro and animal studies.
• Human application requires nuanced understanding of resveratrol's oral absorption.

Purpose of the Study:

• To systematically assess oral resveratrol bioavailability in humans using a meta-analysis of clinical trial data.
• To derive insights into resveratrol's efficacy based on human pharmacokinetic parameters.
• To identify optimal dosing strategies considering bioavailability and safety.

Main Methods:

• A comprehensive meta-analysis of clinical trials from major databases (PubMed, Cochrane, Scopus, Embase, Science Direct).
• Inclusion of studies measuring pharmacokinetic parameters after single oral resveratrol doses in healthy adults.
• Data extraction of mean and standard deviation, with assessment of heterogeneity and meta-regression.

Main Results:

• Analyzed 84 oral administrations across nine resveratrol doses (25-5000mg).
• Found a linear increase in free resveratrol plasma levels with increasing dose.
• Observed no significant change in Tmax; mean Cmax at 100-500mg doses (33.59 ng/mL) aligns with overall mean (31.07 ng/mL).

Conclusions:

• Doses between 100-500mg appear appropriate for resveratrol, balancing bioavailability and low side effect risk.
• Methodological inconsistencies in human oral bioavailability studies limit current analysis.
• Substantial heterogeneity necessitates further rigorous clinical trials to confirm findings.